Search research articles
Contact Us
Filters
Showing results (101-110 of 132) with videos related to
Page
of 14
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
July 24, 2012
Tissue pattern recognition error rates and tumor heterogeneity in gastric cancer
Steven J Potts, Sarah E Huff, Holger Lange, et al.
Archives of Pathology & Laboratory Medicine
|
April 28, 2009
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines
Gail H Vance, Todd S Barry, Kenneth J Bloom, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
June 15, 2007
Defining the expression pattern of the LGI1 gene in BAC transgenic mice
Karen Head, Shiaoching Gong, Sheldon Joseph, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
October 12, 2011
Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)
Ya-Hui Chiu, Kofi A Mensah, Edward M Schwarz, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 29, 2024
Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype
Rana Ajabnoor, Gloria Zhang, Yan Hu, et al.
Archives of Pathology & Laboratory Medicine
|
September 14, 2013
Folate receptor α associated with triple-negative breast cancer and poor prognosis
Zhang Zhang, Jianmin Wang, David E Tacha, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
July 20, 2021
HER2 Testing: Insights From Pathologists' Perspective on Technically Challenging HER2 FISH Cases
Erin V Grimm, Kimberly H Allison, David G Hicks, et al.
Cancers
|
February 11, 2023
The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX<sup>®</sup> Testing
Bradley M Turner, Brian S Finkelman, David G Hicks, et al.
Human Pathology
|
May 13, 2024
Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas
Janira M Navarro Sanchez, Brian S Finkelman, Haley Tyburski, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B
|
November 29, 2007
Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience
Raymond R Tubbs, David G Hicks, James Cook, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 132) with videos related to
Sort By:
Page
of 14
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
July 24, 2012
Tissue pattern recognition error rates and tumor heterogeneity in gastric cancer
Steven J Potts, Sarah E Huff, Holger Lange, et al.
Archives of Pathology & Laboratory Medicine
|
April 28, 2009
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines
Gail H Vance, Todd S Barry, Kenneth J Bloom, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
June 15, 2007
Defining the expression pattern of the LGI1 gene in BAC transgenic mice
Karen Head, Shiaoching Gong, Sheldon Joseph, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
October 12, 2011
Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)
Ya-Hui Chiu, Kofi A Mensah, Edward M Schwarz, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 29, 2024
Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype
Rana Ajabnoor, Gloria Zhang, Yan Hu, et al.
Archives of Pathology & Laboratory Medicine
|
September 14, 2013
Folate receptor α associated with triple-negative breast cancer and poor prognosis
Zhang Zhang, Jianmin Wang, David E Tacha, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
July 20, 2021
HER2 Testing: Insights From Pathologists' Perspective on Technically Challenging HER2 FISH Cases
Erin V Grimm, Kimberly H Allison, David G Hicks, et al.
Cancers
|
February 11, 2023
The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX<sup>®</sup> Testing
Bradley M Turner, Brian S Finkelman, David G Hicks, et al.
Human Pathology
|
May 13, 2024
Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas
Janira M Navarro Sanchez, Brian S Finkelman, Haley Tyburski, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B
|
November 29, 2007
Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience
Raymond R Tubbs, David G Hicks, James Cook, et al.
Page
of 14